Zypher Lifesciences Private Limited

Zypher Lifesciences Private Limited, established on March 19, 2007, is a privately held pharmaceutical company headquartered in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U29297DL2007PTC160681. Initially incorporated with an authorized and paid-up capital of ₹100,000, Zypher Lifesciences has since expanded its operations and capital base.

The company's registered office is located at Unit No 308-309, Jaksons Crown Heights, Plot No 381, Twin District Centre, Sector-10, Rohini, New Delhi, Delhi, 110085, India. Zypher Lifesciences specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to various therapeutic categories. The company has demonstrated a consistent growth trajectory, with a reported compound annual growth rate (CAGR) of 20%, reflecting its expanding product portfolio and market presence.

Zypher Lifesciences operates state-of-the-art manufacturing facilities in India, designed to meet stringent regulatory standards. The facilities are equipped with advanced machinery and instruments, ensuring compliance with Good Manufacturing Practices (GMP) and other international quality standards. These plants are accredited by the Italian Medicines Agency (AIFA) for manufacturing commercial drug products for the European Union market, and also hold approvals from the Ministry of Health of the Republic of Turkey.

The leadership team at Zypher Lifesciences comprises directors Aditya Bhatia, Gunjan Bhatia, and Anita Bhatia. Aditya Bhatia serves as a director, with Gunjan Bhatia and Anita Bhatia also holding directorial positions. The company's strategic direction and growth initiatives are guided by this experienced leadership team, focusing on expanding product offerings and enhancing global market presence.

Zypher Lifesciences has established a presence in several regulated markets, including the European Union (EU) and Turkey. The company's manufacturing facilities are approved by the Italian Medicines Agency (AIFA), allowing it to supply commercial drug products to the EU market. Additionally, the facilities have received approval from the Ministry of Health of the Republic of Turkey, facilitating market access in Turkey. These regulatory approvals underscore the company's commitment to adhering to international quality standards and expanding its footprint in regulated markets.

Zypher Lifesciences has extended its reach into emerging markets across Asia, Africa, the Commonwealth of Independent States (CIS), the Middle East and North Africa (MENA) region, Russia, and Latin America. The company's marketing strategy in these regions focuses on enhancing visibility and connecting with customers and business associates. While specific details regarding WHO prequalification are not available, the company's adherence to international quality standards positions it favorably for market penetration in these regions.

Zypher Lifesciences demonstrates a diversified geographic strategy by operating in both regulated and emerging markets. This approach mitigates concentration risk and leverages growth opportunities across different regions. The company's focus on expanding its presence in emerging markets, while maintaining compliance with regulatory standards in developed markets, reflects a balanced and strategic direction aimed at sustainable growth.

Specific details regarding Zypher Lifesciences' interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly available. The company's current focus appears to be on markets with established regulatory approvals, such as the EU and Turkey.

Zypher Lifesciences' manufacturing facilities are accredited by the Italian Medicines Agency (AIFA) for compliance with EU Good Manufacturing Practice (GMP) standards. This accreditation allows the company to manufacture and supply pharmaceutical products to the EU market. Additionally, the facilities have received approval from the Ministry of Health of the Republic of Turkey, indicating adherence to international quality standards.

Specific details regarding Zypher Lifesciences' compliance with the Central Drugs Standard Control Organisation (CDSCO) and other Indian regulatory bodies, including manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs), are not publicly available. The company's adherence to international quality standards suggests compliance with domestic regulatory requirements.

There are no publicly available records of recent regulatory actions, such as Form 483 observations, warning letters, or import alerts, associated with Zypher Lifesciences. The company's focus on maintaining high-quality standards and obtaining international accreditations indicates a proactive approach to regulatory compliance.

Zypher Lifesciences operates in a competitive pharmaceutical industry, with numerous companies offering similar products across various therapeutic categories. While specific market share data is not available, the company's focus on niche formulations in hormones and oncology, along with its international accreditations, positions it as a specialized player in these segments. The company's expansion into emerging markets further enhances its competitive positioning.

Zypher Lifesciences' key differentiators include its specialization in niche formulations, particularly in hormones and oncology, and its adherence to international quality standards, as evidenced by certifications from AIFA and the Ministry of Health of the Republic of Turkey. The company's commitment to Quality by Design (QbD) principles ensures that quality is integrated into the product development process, leading to high-quality pharmaceutical products.

Zypher Lifesciences is strategically positioned as a manufacturer of generic pharmaceutical formulations, with a focus on niche segments such as hormones and oncology. The company's adherence to international quality standards and its expansion into both regulated and emerging markets reflect a strategic direction aimed at sustainable growth and global market presence. Future outlooks suggest continued emphasis on product diversification and market expansion.

Zypher Lifesciences has demonstrated a consistent track record in pharmaceutical manufacturing, with a reported compound annual growth rate (CAGR) of 20%, indicating reliable export volume and consistency. The company's adherence to international quality standards, as evidenced by certifications from AIFA and the Ministry of Health of the Republic of Turkey, underscores its reliability as a supplier.

Importers should verify the following certifications when considering Zypher Lifesciences as a supplier:

• WHO-GMP Certification: To ensure compliance with World Health Organization Good Manufacturing Practices.

• EU GMP Certification: To confirm adherence to European Union Good Manufacturing Practices.

• ISO Certifications: To assess the company's quality management systems.

These certifications can typically be verified through the company's official website or by contacting the relevant regulatory bodies.

When conducting due diligence on Zypher Lifesciences, consider the following steps:

• Verify Regulatory Approvals: Confirm certifications such as WHO-GMP, EU GMP, and ISO through official channels.

• Assess Financial Health: Review the company's financial statements and credit history.

• Evaluate Product Quality: Request product samples and assess quality standards.

• Check Compliance Records: Investigate any past regulatory actions or compliance issues.

• Review Supply Chain Practices: Assess the reliability and efficiency of the company's supply chain.

Red flags to watch for include inconsistent product quality, lack of transparency in operations, and unresolved regulatory issues. Recommended pre-order checks involve verifying certifications, assessing financial stability, and evaluating product quality to ensure a reliable partnership.